Tyra Biosciences, Inc. (TYRA) Revenue, Earnings & Financial Statements
$19.57NASDAQ: TYRAMarket Cap $1.35B
Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)
Tyra Biosciences, Inc. most recently reported annual revenue of $0, a net loss of $120.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Tyra Biosciences, Inc.: net profit was positive in 0 of 7 reported years; the most recent year shows a net loss of $120.0M.
Income Statement — 7 Years (USD millions)
Metric
2019
2020
2021
2022
2023
2024
2025
Revenue
$0
$0
$0
$0
$0
$0
$0
Operating Expenses
$3.0M
$9.0M
$26.0M
$59.0M
$80.0M
$104.0M
$133.0M
Operating Profit
−$3.0M
−$9.0M
−$26.0M
−$59.0M
−$80.0M
−$104.0M
−$133.0M
Other Income
−$1.0M
$0
$0
$4.0M
$11.0M
$18.0M
$13.0M
Interest
$0
$0
$0
$0
$0
$0
$0
Depreciation
$0
$0
$0
$0
$0
$1.0M
$1.0M
Profit Before Tax
−$4.0M
−$9.0M
−$26.0M
−$55.0M
−$69.0M
−$86.0M
−$120.0M
Tax rate (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Net Profit
−$4.0M
−$9.0M
−$26.0M
−$55.0M
−$69.0M
−$86.0M
−$120.0M
EPS
−$0.10
−$0.22
−$0.63
−$1.32
−$1.62
−$1.51
−$2.01
Quarterly Results — Last 12 Quarters (USD millions)
8 duplicate period labels in the source data were collapsed.
Metric
Dec '23
Mar '24
Jun '24
Sep '24
Dec '24
Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Jun '26
Sep '26
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Operating Expenses
$26.0M
$22.0M
$24.0M
$29.0M
$30.0M
$32.0M
$31.0M
$33.0M
$37.0M
$42.0M
$49.0M
$55.0M
Operating Profit
−$26.0M
−$22.0M
−$24.0M
−$29.0M
−$30.0M
−$32.0M
−$31.0M
−$33.0M
−$37.0M
−$42.0M
−$49.0M
−$55.0M
Interest
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Profit Before Tax
−$23.0M
−$18.0M
−$19.0M
−$24.0M
−$26.0M
−$28.0M
−$28.0M
−$30.0M
−$34.0M
−$39.0M
−$46.0M
−$51.0M
Tax rate (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Net Profit
−$23.0M
−$18.0M
−$19.0M
−$24.0M
−$26.0M
−$28.0M
−$28.0M
−$30.0M
−$34.0M
−$39.0M
−$46.0M
−$51.0M
EPS
−$0.53
−$0.35
−$0.32
−$0.41
−$0.43
−$0.47
−$0.47
−$0.50
−$0.57
−$0.64
−$0.69
−$0.74
Over the 7 years reported for Tyra Biosciences, Inc., cash stood at $77.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 14.72 times.
Balance Sheet — 7 Years (USD millions)
Metric
2019
2020
2021
2022
2023
2024
2025
Total Assets
$1.0M
$16.0M
$307.0M
$266.0M
$226.0M
$364.0M
$283.0M
Current Assets
$0
$15.0M
$304.0M
$257.0M
$212.0M
$347.0M
$265.0M
Cash
$0
$15.0M
$302.0M
$251.0M
$58.0M
$92.0M
$77.0M
Inventory
$0
$0
$0
$0
$0
$0
$0
Receivables
$0
$0
$0
$0
$0
$2.0M
$0
Fixed Assets
$0
$0
$2.0M
$4.0M
$8.0M
$8.0M
$7.0M
Capital Work in Progress
$0
$0
$0
$0
$0
$0
$0
Investments
$0
$0
$0
$0
$145.0M
$249.0M
$179.0M
Other Assets
$0
$0
$0
$0
$0
$0
$0
Total Liabilities
$5.0M
$30.0M
$5.0M
$8.0M
$22.0M
$20.0M
$23.0M
Current Liabilities
$5.0M
$2.0M
$4.0M
$6.0M
$15.0M
$15.0M
$18.0M
Borrowings
$0
$0
$1.0M
$3.0M
$6.0M
$6.0M
$6.0M
Other Liabilities
$5.0M
$30.0M
$4.0M
$6.0M
$15.0M
$14.0M
$18.0M
Equity
$0
$0
$0
$0
$0
$0
$0
Reserves
−$5.0M
−$14.0M
$302.0M
$258.0M
$204.0M
$343.0M
$259.0M
For Tyra Biosciences, Inc., operating cash flow was positive in 0 of 7 reported years; free cash flow in the latest year was negative at $95.0M; free cash flow was positive in 0 of 7 years.
Cash Flow Statement — 7 Years (USD millions)
Metric
2019
2020
2021
2022
2023
2024
2025
Operating Cash Flow
−$3.0M
−$8.0M
−$24.0M
−$50.0M
−$50.0M
−$70.0M
−$95.0M
Investing Cash Flow
$0
−$1.0M
−$1.0M
−$1.0M
−$145.0M
−$99.0M
$72.0M
Financing Cash Flow
$0
$0
$1.0M
$0
$0
$2.0M
$0
Net Cash Flow
−$2.0M
$15.0M
$287.0M
−$51.0M
−$193.0M
$34.0M
−$15.0M
Free Cash Flow
−$3.0M
−$8.0M
−$24.0M
−$51.0M
−$51.0M
−$70.0M
−$95.0M
Valuation & Return Ratios
Metric
Value
PEG Ratio
0.24
EV / EBITDA
-5.27
FCF Yield
-8.79%
Quick Ratio
23.93
Interest Coverage
—
Return 1Y
28.45%
Return 3Y
62.41%
Return 5Y
-26.66%
Tyra Biosciences, Inc. (TYRA) financials — frequently asked questions
What is Tyra Biosciences, Inc.'s annual revenue?
Tyra Biosciences, Inc. (TYRA) reported annual revenue of $0 in its most recent fiscal year.
What is Tyra Biosciences, Inc.'s net profit?
Tyra Biosciences, Inc. (TYRA) reported a net loss of $120.0M in its most recent fiscal year.
What is TYRA EV/EBITDA?
Tyra Biosciences, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -5.27. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.
Revenue and earnings of other Biotechnology stocks